Trial · NCT03688542
Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module
NCT03688542, Not applicable, Completed, Anne Niquille; results first posted 2021-04-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module. Trials, record NCT03688542. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03688542
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module
- NCT number
- NCT03688542
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 56 participants, actual
- Lead sponsor
- Anne Niquille
- Conditions
- Polypharmacy, Inappropriate Prescribing
- Interventions
- Quality Circle Deprescribing Module
- First posted
- 2018-09-28
- Last updated
- 2021-04-21
- Results first posted
- 2021-04-21
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Potentially Inappropriate Galenic Units | 12 months | The primary outcome is the percentage, at follow-up, of potentially inappropriate galenic units at follow-up, relative to the total number of galenic units used in the nursing home. |
| Primary | Number of Potentially Inappropriate Defined Daily Doses (DDDs) Per Average Resident and Per Day | 12 months | Sum of Defined Daily Doses identified as potentially inappropriate (PIM, see protocol for assessement method), divided by the total number of days spent in the NH |
| Secondary | Number of Potentially Inappropriate DDD to Avoid | 12 months | Sum of Defined Daily Doses identified as "to avoid" (see protocol for assessement method), divided by the total number of days spent in the NH. |
| Secondary | Number of Potentially Inappropriate DDD to Reevaluate | 12 months | Sum of Defined Daily Doses identified as "to reevaluate" (see protocol for assessement method), divided by the total number of days spent in the NH. |
| Secondary | Number of Hospital Days | 12 months | The number of days spent in the hospital by average resident |
| Secondary | Mortality Rate | 12 months | Number of residents of the nursing home having died during the considered year, divided by the total number of residents having stayed in the nursing home. |
| Secondary | Number of Falls Per Average Resident and Per Year | 12 months | Number of falls per average resident and per year |
| Secondary | Percentage of Residents With at Least One Day of Physical Restraints Use | 12 months | Number of residents of the nursing home with at least one day of physical restraints use during the considered year, divided by the total number of residents having stayed in the nursing home. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Potentially Inappropriate Galenic Units | 12 months | The analysis level is the nursing home; no data on individual residents were collected | percent | MEAN |
| PRIMARY | Number of Potentially Inappropriate Defined Daily Doses (DDDs) Per Average Resident and Per Day | 12 months | The analysis level is the nursing home; no data on individual residents were collected | PIM DDD per avg resident per day | MEAN |
| SECONDARY | Number of Potentially Inappropriate DDD to Avoid | 12 months | The analysis level is the nursing home; no data on individual residents were collected | Number of PIM DDD per avg resident | MEAN |
| SECONDARY | Number of Potentially Inappropriate DDD to Reevaluate | 12 months | The analysis level is the nursing home; no data on individual residents were collected | Number of PIM DDD per avg resident | MEAN |
| SECONDARY | Number of Hospital Days | 12 months | The analysis level is the nursing home; no data on individual residents were collected | Days per avg resident and per year | MEAN |
| SECONDARY | Mortality Rate | 12 months | The analysis level is the nursing home; no data on individual residents were collected | Percent of residents having died | MEAN |
| SECONDARY | Number of Falls Per Average Resident and Per Year | 12 months | The analysis level is the nursing home; no data on individual residents were collected. | Falls per avg resident and per year | MEAN |
| SECONDARY | Percentage of Residents With at Least One Day of Physical Restraints Use | 12 months | The analysis level is the nursing home; no data on individual residents were collected. | Proportion of res with phys restraints | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Potentially Inappropriate Galenic Units | Intervention | 24 | Standard Deviation 7 | percent | |
| Percentage of Potentially Inappropriate Galenic Units | Control | 23 | Standard Deviation 9 | percent | |
| Number of Potentially Inappropriate Defined Daily Doses (DDDs) Per Average Resident and Per Day | Intervention | 2.1 | Standard Deviation 0.5 | PIM DDD per avg resident per day | |
| Number of Potentially Inappropriate Defined Daily Doses (DDDs) Per Average Resident and Per Day | Control | 2.3 | Standard Deviation 0.5 | PIM DDD per avg resident per day | |
| Number of Potentially Inappropriate DDD to Avoid | Intervention | 0.3 | Standard Deviation 0.2 | Number of PIM DDD per avg resident | |
| Number of Potentially Inappropriate DDD to Avoid | Control | 0.3 | Standard Deviation 0.2 | Number of PIM DDD per avg resident | |
| Number of Potentially Inappropriate DDD to Reevaluate | Intervention | 1.8 | Standard Deviation 0.5 | Number of PIM DDD per avg resident | |
| Number of Potentially Inappropriate DDD to Reevaluate | Control | 2.0 | Standard Deviation 0.5 | Number of PIM DDD per avg resident | |
| Number of Hospital Days | Intervention | 3.1 | Standard Deviation 1.5 | Days per avg resident and per year | |
| Number of Hospital Days | Control | 2.5 | Standard Deviation 1.7 | Days per avg resident and per year |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention | 0 | 27 |
| Overall Study | STARTED | Control | 0 | 29 |
| Overall Study | COMPLETED | Intervention | 0 | 27 |
| Overall Study | COMPLETED | Control | 0 | 28 |
| Overall Study | NOT COMPLETED | Intervention | 0 | 0 |
| Overall Study | NOT COMPLETED | Control | 0 | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention | 921 | 2,899 |
| Total, all-cause mortality | Control | 717 | 2,113 |
| Total, other adverse events | Intervention | 0 | 0 |
| Total, other adverse events | Control | 0 | 0 |
| Total, serious adverse events | Intervention | 0 | 0 |
| Total, serious adverse events | Control | 0 | 0 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Intervention vs Control: deaths from any cause |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03688542
GET https://conductscience.org/api/trials/v1/NCT03688542/registered